Research Library / GH Axis / Tesamorelin
GH Axis researchTesamorelin (Egrifta SV)
Egrifta WR · Egrifta SV · TH9507
A stabilized GHRF analog approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The listed community example (community research-vial range) describes 1–2 mg per administration, once daily, via subcutaneous; this is not a validated dosing recommendation. The 2 mg EGRIFTA SV vial reference retains its labeled 4 mg/mL concentration and exact product-specific diluent. For research and education only, not personal medical guidance.
Quick Reference
- Product reference
- 2mg
- Product-specific diluent
- 0.5 mL supplied Sterile Water for InjectionUse exact product instructions
- Concentration
- 4 mg/mLLabeled deliverable concentration
- One U-100 marking
- See product referenceVolume marks are not peptide IU
These labeled product instructions cannot be transferred to generic research vials or another product presentation.
Research schedules
| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| EGRIFTA WR label schedule | 1.28 mg | 1.28 mg/day | Once daily | Consistent daily time | Subcutaneous abdomen | Trial-derived reference |
| EGRIFTA SV label schedule | 1.4 mg | 1.4 mg/day | Once daily | Consistent daily time | Subcutaneous abdomen | Trial-derived reference |
1.28 mg in 0.16 mL · subcutaneous · once daily · 11.6 mg vial reconstituted with 1.3 mL supplied bacteriostatic water
Adults with HIV and lipodystrophy with excess abdominal fatFDA prescribing information, 2025Reported schedule context
- Range
- 1–2 mg/day in community reports; approved products use 1.28 mg or 1.4 mg daily
- Frequency
- Daily
- Route
- Subcutaneous
- Reported half-life
- ~26–38 minutes
- Reported cycle
- Study-, label- and formulation-dependent
EGRIFTA WR and EGRIFTA SV are not interchangeable; the trial-derived rows and reconstitution cards retain their separate label instructions.
Cross-reference reviewed October 2026. Half-life and cycles retain this source context.| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Community research-vial range | 1–2 mg | 1–2 mg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Product-specific labeled reference
- Vial
- 2 mg EGRIFTA SV vial
- Diluent
- 0.5 mL supplied Sterile Water for Injection
- Concentration
- 4 mg/mL
- Labeled amount
- 1.4 mg labeled dose
- Volume
- 0.35 mL
- U-100 equivalent
- 35 units
Generic mass/volume editing is disabled for this labeled preparation. Its deliverable concentration must be taken from the exact product label.
Original example & formulation context
1.4 mg labeled dose · 4 mg/mL · 0.35 mL · 35 units
Product-specific labeled example. EGRIFTA SV must use its supplied sterile-water diluent; it is not interchangeable with EGRIFTA WR or a generic 10 mg research vial.
Supplies & vial yield
10 mg vial · 2 mL assumed final solution volume per vial · 5 days on / 2 days off
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Weeks 1–2 | 1 mg per administration | 5 times weekly | 5 mg/week |
| Week 3 onward | 2 mg per administration | 5 times weekly | 10 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 8 weeks | 70 mg | 7 × 10 mg |
| 12 weeks | 110 mg | 11 × 10 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 8 weeks | 14 mL | Not established |
| 12 weeks | 22 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 8 weeks | 40 |
| 12 weeks | 60 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
8 weeks: 2 weeks initially; 1 week after escalation
12 weeks: 2 weeks initially; 1 week after escalation
Applies to the original planning basis above; not a product stability period.
The seven-vial 8-week total assumes five administrations per week. Vial counts are rounded up. Liquid totals are conditional final-volume arithmetic, not verified diluent quantities; the actual product must specify the diluent and amount to add.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Tesamorelin · Egrifta WR · Egrifta SV · TH9507
- Evidence / status
- FDA approved. FDA approved for a specific HIV-associated indication; not approved for weight management
- Clinical route, frequency & duration
Current EGRIFTA WR labeling: 1.28 mg in 0.16 mL · subcutaneous · once daily · 11.6 mg vial reconstituted with 1.3 mL supplied bacteriostatic water
- Community purpose
- GH-axis stimulation; clinically used for HIV-associated excess visceral abdominal fat and discussed more broadly for body composition.
- Reported timing / route
- Daily · Subcutaneous. Schedule-specific timing remains in the Community tab.
- Reported half-life
- ~26–38 minutes · community-reference context, not a shelf life.
- Reported cycle
- Study-, label- and formulation-dependent. Planning horizons do not establish a validated cycle.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
EGRIFTA SV specifies its supplied Sterile Water for Injection; EGRIFTA WR specifies its supplied Bacteriostatic Water for Injection. Their preparation and post-reconstitution storage rules differ.
Other vehicles and approaches discussed
The labeled examples below remain product-specific. Neither product instruction validates a generic 10 mg vial, a blend, acid addition or another solvent substitution.
- Evidence context
- Product / laboratory / report distinctions apply
- Cloudiness / gel signal
- Distinct labeled diluents; community clouding reports separate
- Product details to verify
- Verify the exact product, sequence/salt form, buffer and excipients, concentration, route, container and product-specific storage instructions.
Sources apply to the named product, laboratory method or report only. Laboratory solvents and community repetition do not establish an injectable preparation, sterility, chemical stability or a beyond-use period. No solvent-mixing or salvage recipe is provided.
Preparation references reviewed October 20, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Distinct labeled diluents; community clouding reports separate
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Growth hormone–releasing factor analog
A stabilized GHRF analog approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. EGRIFTA WR and EGRIFTA SV use different doses, vial strengths, diluents and storage instructions and are not substitutable.
Community-reported purpose
GH-axis stimulation; clinically used for HIV-associated excess visceral abdominal fat and discussed more broadly for body composition.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Current EGRIFTA WR labeling
Protocol: 1.28 mg in 0.16 mL · subcutaneous · once daily · 11.6 mg vial reconstituted with 1.3 mL supplied bacteriostatic water
Population: Adults with HIV and lipodystrophy with excess abdominal fat
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Labeling warns about malignancy, elevated IGF-1, fluid retention, glucose intolerance, hypersensitivity and uncertain long-term cardiovascular safety. It is not indicated for weight loss management.
Development and regulatory status
FDA approved for a specific HIV-associated indication; not approved for weight management
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Tesamorelin?
A stabilized GHRF analog approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. EGRIFTA WR and EGRIFTA SV use different doses, vial strengths, diluents and storage instructions and are not substitutable.
Growth hormone–releasing factor analog
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Study-, label- and formulation-dependent
Which diluent and storage period should this material use?
EGRIFTA SV specifies its supplied Sterile Water for Injection; EGRIFTA WR specifies its supplied Bacteriostatic Water for Injection. Their preparation and post-reconstitution storage rules differ.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeFDA prescribing information, 2025: Current EGRIFTA WR labeling
- Product labelEGRIFTA SV FDA label
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.